FORE Biotherapeutics has completed target enrolment in the primary central [...]

A peer-reviewed study published in Therapeutic Innovation & Regulatory Science [...]

Ananda Pharma has begun participant screening for a Phase 2 [...]

Novartis has agreed to acquire UK biotech Myricx Bio for [...]

Telix Pharmaceuticals has received FDA agreement on the protocol and [...]

Lonza will expand its highly potent active pharmaceutical ingredient manufacturing [...]

NICE has recommended cemiplimab for eligible adults with recurrent or [...]

InduPro has licensed Lonza’s antibody-drug conjugate technologies to support development [...]

The European Commission has approved BRAFTOVI in combination with cetuximab [...]

Lonza has entered an exclusive licensing agreement with Antharis Therapeutics [...]